Contact Us

PW Case Review Form
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 


   * Please describe your case:

What injury have you suffered?

For verification purposes, please answer the below question:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Parker Waichman Files 3 Dozen Fosamax Lawsuits on Single Day

Mar 15, 2012 | Parker Waichman LLP

Parker Waichman LLP has filed three dozen lawsuits on behalf of women who allegedly suffered Fosamax femur fractures after using the bisphosphonate for several years.  All 36 of the Fosamax femur fracture lawsuits were filed by Parker Waichman LLP on  March 5,  in the Superior Court of New Jersey, Law Division, Atlantic County, where lawsuits involving alleged Fosamax side effects have been designated a mass tort (In re: Fosamax Litigation (No. 282 NJ. Super. Ct.)

All of the complaints name Merck Sharp & Dohme Corp. f/k/a Merck & Co., Watson Pharmaceuticals, Inc. and Teva Pharmaceuticals USA, Inc. as Defendants.  The lawsuits allege that as a direct and proximate result of their long-term use of Fosamax, the Plaintiffs suffered severe mental and physical pain and suffering, and have and will continue to sustain permanent injuries and emotional distress, along with economic losses resulting from medical expenses and living-related expenses related to their new lifestyle. All of the claims seek compensatory, punitive and treble damages, as well as ascertainable economic losses, reimbursement of the cost of Fosamax, reimbursement for all past, present and future health and medical costs related to Fosamax per quod, and derivative damages on behalf of the plaintiffs.

Fosamax and other bisphosphonates are used to treat osteoporosis in post-menopausal women and other bone disorders, including Paget's disease. In October 2010, the U.S. Food & Drug Administration asked the manufacturers of bisphosphonates used to treat osteoporosis, including Fosamax, to add information to the "Warnings and Precautions" section of the drugs’ labels describing the risk of atypical thigh fractures after a study linked long-term use of such drugs to this side effect.

According to Parker Waichman attorney Matthew McCauley, these three dozen Fosamax lawsuits are unlikely to be the last filed by the firm. 

"Parker Waichman LLP is hearing from women on an almost daily basis who sustained life-changing injuries similar to those suffered by our plaintiffs after using Fosamax for years,” he said.

As the leading attorney in the Bisphosphonate Litigation Group at Parker Waichman LLP, McCauley is currently investigating bisphosphonate related femur fracture.

Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo